QURE has been in the news 341% more than usual
Mar 02, 2026, 3:32 PM
56.00%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
QURE has been in the news recently: The Schall Law Firm and DJS Law Group have announced class action lawsuits against uniQure N.V. for making misleading statements that affected the company's shares during a specified period in 2025. Additionally, uniQure's gene therapy AMT-130 for Huntington's disease will not be supported by FDA Phase 1/2 study data for marketing.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.